CN107109488A - 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法 - Google Patents

预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法 Download PDF

Info

Publication number
CN107109488A
CN107109488A CN201580068041.7A CN201580068041A CN107109488A CN 107109488 A CN107109488 A CN 107109488A CN 201580068041 A CN201580068041 A CN 201580068041A CN 107109488 A CN107109488 A CN 107109488A
Authority
CN
China
Prior art keywords
basal
breast cancer
subject
classifier score
androgen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580068041.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·C·彼得森
H·乌帕尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mai Diweixun Prostate Treatment Ltd Co
Original Assignee
Mai Diweixun Prostate Treatment Ltd Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mai Diweixun Prostate Treatment Ltd Co filed Critical Mai Diweixun Prostate Treatment Ltd Co
Publication of CN107109488A publication Critical patent/CN107109488A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201580068041.7A 2014-12-12 2015-12-08 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法 Pending CN107109488A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462091195P 2014-12-12 2014-12-12
US62/091,195 2014-12-12
US201562142504P 2015-04-03 2015-04-03
US62/142,504 2015-04-03
US201562167110P 2015-05-27 2015-05-27
US62/167,110 2015-05-27
PCT/US2015/064500 WO2016094408A1 (en) 2014-12-12 2015-12-08 Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Publications (1)

Publication Number Publication Date
CN107109488A true CN107109488A (zh) 2017-08-29

Family

ID=55273509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580068041.7A Pending CN107109488A (zh) 2014-12-12 2015-12-08 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法

Country Status (15)

Country Link
US (3) US10196693B2 (https=)
EP (2) EP3604556A1 (https=)
JP (1) JP6735277B2 (https=)
KR (1) KR20170095306A (https=)
CN (1) CN107109488A (https=)
AU (1) AU2015360767A1 (https=)
BR (1) BR112017012142A2 (https=)
CA (1) CA2970469A1 (https=)
ES (1) ES2748005T3 (https=)
IL (1) IL252587A0 (https=)
MX (1) MX2017007707A (https=)
RU (1) RU2017120330A (https=)
SG (1) SG11201704425TA (https=)
WO (1) WO2016094408A1 (https=)
ZA (1) ZA201703904B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109735625A (zh) * 2019-03-18 2019-05-10 马榕 乳头溢液在检测肿瘤相关基因中的应用
WO2020001473A1 (zh) * 2018-06-28 2020-01-02 复旦大学 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途
CN114334000A (zh) * 2021-12-28 2022-04-12 上海中医药大学 基于转录组图谱的组合药物生成方法、系统及存储介质

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843417C (en) 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
CN107109488A (zh) * 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法
WO2016201299A1 (en) 2015-06-12 2016-12-15 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
KR101966493B1 (ko) * 2016-06-27 2019-04-05 국립암센터 삼중음성유방암 예후 예측용 바이오마커
KR101896558B1 (ko) * 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN110573958A (zh) * 2017-04-26 2019-12-13 日本电信电话株式会社 N×n光开关
EP3635130A4 (en) 2017-05-12 2021-06-09 Indiana University Research and Technology Corporation Precision medicine for treating and preventing suicidality
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
KR102542275B1 (ko) * 2018-05-14 2023-06-12 하이노바 파마슈티컬스 인코포레이티드 Hc-1119 제제 및 그 제조방법 및 용도
US20260043086A1 (en) * 2022-08-06 2026-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917982A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与其他抗肿瘤剂组合治疗乳腺癌
CN103997894A (zh) * 2011-07-29 2014-08-20 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6937713B1 (en) 1999-12-30 2005-08-30 At&T Corp. IP call forward profile
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
US20070059720A9 (en) 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
SG173837A1 (en) 2009-02-24 2011-09-29 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
WO2010125117A2 (en) 2009-04-29 2010-11-04 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
JP2013504064A (ja) 2009-09-03 2013-02-04 ザ スクリプス リサーチ インスティチュート 循環腫瘍細胞を分類する方法
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) * 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
US8781912B2 (en) 2011-03-15 2014-07-15 Opera Solutions, Llc Computer-based method and computer program product for setting floor prices for items sold at auction
JP6144695B2 (ja) 2011-11-30 2017-06-07 ユニバーシティー オブ ノースカロライナ アット チャペル ヒル タキサン療法を用いて乳癌を処置する方法
ES2696202T3 (es) 2012-08-23 2019-01-14 Univ Colorado Regents Método para determinar el tratamiento de cáncer de mama
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) * 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
CN107109488A (zh) 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101917982A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与其他抗肿瘤剂组合治疗乳腺癌
CN103997894A (zh) * 2011-07-29 2014-08-20 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUTOSHI AKIYAMA等: "Triple Negative Breast Cancer: Clinicopathological Characteristics and Treatment Strategies", 《BREAST CANCER》 *
林能明等: "《新编抗肿瘤药物学》", 31 May 2014, 军事医学科学出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020001473A1 (zh) * 2018-06-28 2020-01-02 复旦大学 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途
CN109735625A (zh) * 2019-03-18 2019-05-10 马榕 乳头溢液在检测肿瘤相关基因中的应用
CN114334000A (zh) * 2021-12-28 2022-04-12 上海中医药大学 基于转录组图谱的组合药物生成方法、系统及存储介质

Also Published As

Publication number Publication date
US11186876B2 (en) 2021-11-30
WO2016094408A1 (en) 2016-06-16
US10196693B2 (en) 2019-02-05
EP3604556A1 (en) 2020-02-05
RU2017120330A (ru) 2019-01-14
RU2017120330A3 (https=) 2019-07-24
KR20170095306A (ko) 2017-08-22
AU2015360767A1 (en) 2017-06-08
EP3230471A1 (en) 2017-10-18
JP2018504892A (ja) 2018-02-22
ZA201703904B (en) 2019-12-18
ES2748005T3 (es) 2020-03-12
US20220056541A1 (en) 2022-02-24
EP3230471B1 (en) 2019-08-28
SG11201704425TA (en) 2017-06-29
CA2970469A1 (en) 2016-06-16
US20160168646A1 (en) 2016-06-16
BR112017012142A2 (pt) 2018-01-02
US11952634B2 (en) 2024-04-09
MX2017007707A (es) 2018-03-06
US20190169697A1 (en) 2019-06-06
IL252587A0 (en) 2017-07-31
JP6735277B2 (ja) 2020-08-05

Similar Documents

Publication Publication Date Title
AU2012345789B2 (en) Methods of treating breast cancer with taxane therapy
CN107109488A (zh) 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法
KR102754524B1 (ko) 유방암 치료를 위한 진단 및 치료 방법들
AU2015334841B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
CN110382521B (zh) 从氧化应激区分肿瘤抑制性foxo活性的方法
RU2719194C2 (ru) Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов
RU2721130C2 (ru) Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
US20030087266A1 (en) IGs as modifiers of the p53 pathway and methods of use
WO2002086443A2 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
CN112795650A (zh) 使用靶基因表达的数学建模评价pi3k细胞信号传导途径活性
CN101573453A (zh) 使用生物学途径基因表达分析来预测淋巴结阴性原发性乳腺癌的远处转移的方法
CN111448325A (zh) 使用靶基因表达的数学建模评估jak-stat3细胞信号传导途径活性
CN115380123A (zh) 基于t细胞受体信号传导基因对前列腺癌对象的放疗反应的预测
US12366575B2 (en) Chemical compositions and methods of use
KR101695866B1 (ko) 전립선 암 마커로서의 포스포디에스테라제 9ａ
CN114450591A (zh) 基于确定fgfr的分类样本的方法
CN101778954A (zh) Egfr抑制剂治疗的预测性标记物
KR20190126812A (ko) 질환 진단용 바이오마커
KR20190032068A (ko) 이차성 급성골수성백혈병으로의 이행 여부 판별용 바이오마커 조성물 및 그 검출 방법
KR20130087585A (ko) 저도 염증을 검출하는 방법
HK1240626A1 (en) Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
HK40057217A (en) Diagnostic and therapeutic methods for the treatment of breast cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: American California

Applicant after: Maddie Wilson prostate Medical Co., Ltd.

Address before: American California

Applicant before: Mai Diweixun prostate treatment limited company

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240626

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1240626

Country of ref document: HK